文献速递前列腺癌

基因工程小鼠模型与人类前列腺癌的共临床分析揭示NKX3.1表达对5α-还原酶抑制剂反应的意义

Co-clinical Analysis of a Genetically Engineered Mouse Model and Human Prostate Cancer Reveals Significance of NKX3.1 Expression for Response to 5α-reductase Inhibition.
PubMed 文献 · Eur Urol · 2017-04-04

本研究用Nkx3.1突变小鼠(早期前列腺癌模型)接受非那雄胺治疗,并进行组织病理与分子分析,同时与两个独立接受5-ARI治疗的患者队列进行跨物种计算分析。结果显示非那雄胺显著减少小鼠前列腺上皮内瘤变(PIN),且NKX3.1表达降低可预测患者对5-ARI的反应。作者认为低NKX3.1表达患者可能是主动监测期间5-ARI干预的最佳候选者。

要点

  • 非那雄胺治疗Nkx3.1突变小鼠后,前列腺上皮内瘤变(PIN)显著减少。
  • 跨物种计算分析显示,NKX3.1表达降低可预测患者对5-ARI的反应。
  • 作者提出低NKX3.1表达患者可能是主动监测期间5-ARI干预的最佳候选者。

核心结论

  • 本共临床研究提示NKX3.1状态是5-ARI反应的预测因子,并提示包括NKX3.1表达在内的分子特征可能有助于识别在主动监测期间最可能从5-ARI获益的前列腺癌患者。

研究设计与样本

  • Nkx3.1突变小鼠(早期前列腺癌模型)接受5-ARI非那雄胺治疗,并进行组织病理学和分子分析;采用跨物种计算分析比较治疗小鼠与前列腺切除术前接受5-ARI治疗患者的表达谱;5-ARI治疗患者标本为回顾性获取。

主要发现

  • 非那雄胺治疗Nkx3.1突变小鼠导致前列腺上皮内瘤变(PIN)显著减少,组织病理学和表达谱分析均显示此结果。
  • 跨物种计算分析比较非那雄胺治疗小鼠与两个独立5-ARI治疗患者队列,显示NKX3.1表达降低可预测对5-ARI的反应。

临床怎么用

  • 作者提出低NKX3.1表达患者是5α-还原酶抑制剂作为主动监测辅助干预的最佳候选者。
  • 作者认为分子特征包括NKX3.1表达可能有助于识别最可能从主动监测期间5-ARI获益的前列腺癌患者。

局限性

  • 这些回顾性人类队列患者相对较少,临床结局数据有限。
  • 未来需要前瞻性临床试验验证基于NKX3.1表达分层是否能改善主动监测期间5-ARI的获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although men on active surveillance for prostate cancer (PCa) may benefit from intervention with 5α-reductase inhibitors (5-ARIs), it has not been resolved whether 5-ARIs are effective for delaying disease progression and, if so, whether specific patients are more likely to benefit. OBJECTIVE: To identify molecular features predictive of patient response to 5-ARIs. DESIGN, SETTING, AND PARTICIPANTS: Nkx3.1 mutant mice, a model of early-stage PCa, were treated with the 5-ARI finasteride, and histopathological and molecular analyses were performed. Cross-species computational analyses were used to compare expression profiles for treated mice with those of patients who had received 5-ARIs before prostatectomy. INTERVENTION: Finasteride administered to Nkx3.1 mutant mice. 5-ARI-treated patient specimens obtained retrospectively. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Endpoints in mice included histopathology, immunohistochemistry, and molecular profiling. GraphPad Prism software, R-studio, and Matlab were used for statistical and data analyses. RESULTS AND LIMITATIONS: Finasteride treatment of Nkx3.1 mutant mice resulted in a significant reduction in prostatic intraepithelial neoplasia (PIN), as evident from histopathological and expression profiling analyses. Cross-species computational analysis comparing finasteride-treated mice with two independent 5-ARI-treated patient cohorts showed that reduced NKX3.1 expression is predictive of response to 5-ARI. A limitation of the study is that these retrospective human cohorts have relatively few patients with limited clinical outcome data. Future prospective clinical trials are needed to validate whether stratifying patients on the basis of NKX3.1 expression improves the benefit of 5-ARIs during active surveillance. CONCLUSIONS: This co-clinical study implicates NKX3.1 status as a predictor of response to 5-ARIs, and suggests that molecular features, including NKX3.1 expression, may help to identify PCa patients most likely to benefit from 5-ARIs during active surveillance. PATIENT SUMMARY: The aim of precision cancer prevention is to tailor interventions on the basis of individualized patient characteristics. We propose that patients with low NKX3.1 expression are optimal candidates for intervention with 5α-reductase inhibitors as an adjunct to active surveillance.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Dutta A, Panja S, Virk RK, et al. Co-clinical Analysis of a Genetically Engineered Mouse Model and Human Prostate Cancer Reveals Significance of NKX3.1 Expression for Response to 5α-reductase Inhibition. Eur Urol. 2017. PMID: 28385453. doi:10.1016/j.eururo.2017.03.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。